The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

Inclusion Criteria: 1. 18 - 65 years old; 2. Chronic hepatitis B patients with clear diagnosis of hematology, etiology and clinical (for example: HBsAg positive for more than 6 months); 3. Treatment with NAs (ETV, TDF or TAF）at least 1 years and continue NAs therapy during screening; 4. HBV DNA and HBeAg turn negative after NAs treatment; 5. HBsAg ranged 200-1000 IU/ml. Exclusion Criteria: 1. Cirrhosis; 2. platelet count \< 90×10\^9/L, WBC count \< 3.0×10\^9/L, neutrophil count \< 1.3×10\^9/L, ALT \> ULN（40U/L）, total bilirubin \> 2ULN; 3. History of or suspicion of hepatocellular carcinoma 4. Patients received interferon therapy within 12 months; 5. Patients received immunosuppressive therapy or other therapy influenced study within 12 months; 6. Hepatitis A, hepatitis C, hepatitis D, HIV infection or other active infections; 7. Alcohol or drug abuse/dependence; 8. Investigator judges that the participants are not suitable for this study.